On 25 August 2025, Vibrant Therapeutics (Guangzhou) Co., Ltd. ("Vibrant"), an innovative company focused on the R&D of next-generation intelligent macromolecule drugs, announced the completion of a multi-million dollar Series A financing round. The Series A+ round was led by Apricot Capital, while the Series A round was led by Trinity Innovation Fund, with follow-on investments from existing shareholders including HongShan Capital Group. The funds will be primarily used to advance the company's core pipeline into global clinical trial stages, accelerate the R&D of first-in-class (FIC) and best-in-class (BIC) drugs, and provide more effective treatment options for global patients.
Founded in 2019 by Dr. Luquan Wang, founder of GenScript, Vibrant's core leadership team has an average of over 20 years of experience in macromolecule drug R&D, having held important positions in well-known domestic and international pharmaceutical and biotechnology companies such as Schering-Plough, Merck, and GenScript. Relying on its deep accumulation in the field of tumour immunotherapy, Vibrant focuses on developing next-generation intelligent macromolecule drugs for diseases like solid tumours. Vibrant's independently developed intelligent molecular design platform uses a "dry-wet combination" R&D model, closely integrating computational prediction with experimental verification to achieve an efficient closed loop between design and experiment. This accelerates the screening and optimisation of drug candidates, improves design precision, and addresses current unmet clinical needs. This round of financing will also be used to expand the talent team and further advance self-developed projects.
Dr. Luquan Wang, CEO of Vibrant, said: "There is still a huge unmet need in therapeutic areas such as solid tumours, and next-generation immunotherapy provides new possibilities for breaking through existing treatment bottlenecks. Thanks to the support of new and old investors, we will accelerate the clinical research of our core pipeline, and strive to bring more effective and safer revolutionary therapies to global patients. At the same time, we welcome more like-minded R&D talents to join Vibrant and jointly promote the progress of treatment for diseases like solid tumours."
Dr. Jing Qiang, Managing Partner of Apricot Capital, said: "TCE is gradually showing huge clinical value in tumour and other disease areas, but there are still many problems to be solved and optimised in molecular design and development. Vibrant has strong technical strength and a clear strategic layout. Apricot Capital is optimistic about its team's professional background and execution, and is willing to work with the Vibrant team to build a global leader in next-generation tumour immunotherapy."
Zhang Qing, Executive Director of Trinity Innovation Fund (TIF), said: "TIF has long been following the technological development and clinical application bottlenecks of TCE in tumour treatment. We are very pleased to participate in and witness the rapid development of Vibrant as the lead investor in its Series A financing round. We believe that the TCE technology platform built by the Vibrant team over the years will be a major driver in breaking through the application bottlenecks of TCE in solid tumour treatment and will lay a solid foundation for the company to continuously produce product pipelines with international competitiveness and influence. The A and A+ funds will strongly accelerate the clinical development of core projects and promote TCE therapies with true transformative potential to benefit global patients."
About Vibrant
Vibrant is an innovative company focused on the R&D of next-generation intelligent macromolecule drugs, founded in 2019 by a team of senior drug R&D experts. The company focuses on the field of tumour immunotherapy and is committed to developing globally competitive first-in-class and best-in-class drugs to provide patients with better treatment options.
